Role of oral gut antibiotic on graft rejection in adult living donor liver transplant

Effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant: An open label randomized control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082124

Enrollment

100

Registered

2025-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K74- Fibrosis and cirrhosis of liver

Interventions

Intervention1: Rifaximin with standard of care: Dose 550mg Frequency twice daily Route of administration orally Duration 2 weeks perior to surgery till 1 week post surgery Control Intervention1: Stand

Eligibility

Inclusion criteria

Inclusion criteria: All recipients undergoing living donor liver transplant in ILBS from ethical board clearance

Exclusion criteria

Exclusion criteria: 1.Negative consent 2.Hypersensitivity to Rifaximin 3.Patients undergoing retransplant 4.ALF, ACLF 5.Pediatrics patients 6.Patients on rifaximin

Design outcomes

Primary

Measure	Time frame
Effect of perioperative oral rifaximin on early graft dysfunctionTimepoint: 6 months	—

Secondary

Measure	Time frame
ischemia reperfusion injury (Cathepsin G, CD 86)Timepoint: 6 months;Early graft dysfunction non invasive markers (IL6, IL17) Timepoint: 6 months;To study the effect of perioperative oral rifaximin on infectious complications, EGD related graft loss and in-hospital mortality (90 days)Timepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Nilesh Sadashiv Patil

Institute of liver and biliary sciences

dr.nils.p@gmail.com9911594576

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026